B7-H1 glycoprotein blockade: A novel strategy to enhance immunotherapy in patients with renal cell carcinoma
- 1 November 2005
- Vol. 66 (5) , 10-14
- https://doi.org/10.1016/j.urology.2005.06.010
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic ImmunityCancer Research, 2005
- Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic targetProceedings of the National Academy of Sciences, 2004
- PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T CellsCancer Research, 2004
- Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine ProductionThe Journal of Immunology, 2003
- An Outcome Prediction Model for Patients with Clear Cell Renal Cell Carcinoma Treated with Radical Nephrectomy Based on Tumor Stage, Size, Grade and Necrosis: The Ssign ScoreJournal of Urology, 2002
- Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockadeProceedings of the National Academy of Sciences, 2002
- Erratum: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasionNature Medicine, 2002
- B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretionNature Medicine, 1999
- Characterization of Tumor-Infiltrating Lymphocyte Subsets from Human Renal Cell Carcinoma: Specific Reactivity Defined by Cytotoxicity, Interferon-?? Secretion, and ProliferationJournal of Immunotherapy, 1994
- SURGERY OF RENAL CELL CARCINOMAUrologic Clinics of North America, 1993